ライフサイエンスコーパス: Equipoise

1 efficacy and side effects, the patient is in equipoise.

2 2 operations are considered to have clinical equipoise.

3 g endemic pediatric giardiasis in a state of equipoise.

4 urves, quality variations, and perception of equipoise.

5 e continue to be important areas of clinical equipoise.

6 gator bias in randomized trials and preclude equipoise.

7 knowledge, resulting in a state of community equipoise.

8 23) to understand their individual sense of equipoise about the RCT treatments and their intentions

9 rollment was halted early because of loss of equipoise after positive results for thrombectomy were r

10 The variation provides evidence of equipoise and emphasizes the need for a well-conducted r

11 spective trial is needed to resolve clinical equipoise and explore quality-of-life effects.

12 s limited and we believe at present there is equipoise and further conclusive studies are needed to e

13 arterectomy, and it underscores the clinical equipoise and premise for the National Institute of Heal

14 group data suggest presenting options and/or equipoise before asking patients about preferred decisio

15 It was the aim of this study to assess equipoise between exception candidates and nonexception

16 at the graft is an active participant in the equipoise between tolerance and rejection and warrants m

17 subarachnoid haemorrhage, assuming treatment equipoise, between Sept 12, 1994, and May 1, 2002.

18 Second, clinicians contradicted equipoise by presenting imbalanced descriptions of trial

19 ree commonly recurring practices compromised equipoise communication across the RCTs, irrespective of

20 tifying practices that supported or hindered equipoise communication and (ii) exploring how clinician

21 ntify practices that supported or challenged equipoise communication.

22 f saturates Mb (P50), the analysis yields an equipoise diffusion P(O2) of 1.77 mmHg, where Mb and fre

23 ly only when cellular oxygen falls below the equipoise diffusion P(O2).

24 Based on the DMb, the equipoise diffusion PO2, the PO2 in which Mb-facilitated

25 aimed to investigate how clinicians conveyed equipoise during RCT recruitment appointments across six

26 ials raise distinctive ethical challenges of equipoise, equity, and informed consent.

27 subject of the research faces, and that when equipoise exists between experimental and standard thera

28 than minimal risk when: 1) genuine clinical equipoise exists; 2) all of the treatment options includ

29 unded by non-profit organisations maintained equipoise favouring new therapies over standard ones (47

30 mong patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a r

31 We discuss the distinction between equipoise for patient-important outcomes versus diagnost

32 data from the PHN are now beginning to show equipoise for the two palliative strategies.

33 d to a significant amount of variability and equipoise in the treatment of this condition.

34 Communicating equipoise is a challenging process that is easily disrup

35 Clinicians' difficulties with negotiating equipoise is assumed to undermine recruitment, although

36 If equipoise is not affirmatively achieved in the risk-bene

37 However, the frequency of occurrence of equipoise issues across the RCTs suggests that the findi

38 more high-quality placebo-controlled trials, equipoise may no longer be guaranteed because autologous

39 This systematic review has demonstrated the equipoise necessary for the design of randomized control

40 es to evaluate learning curves and alleviate equipoise problems.

41 This state of equipoise raises the question of whether alternative ant

42 tion therapy and for whom there was clinical equipoise regarding the continuation or cessation of ant

43 onths of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulati

44 PURPOSE There is equipoise regarding the optimal treatment of clinical st

45 An equipoise-stratified design allowed participants to excl

46 An equipoise-stratified randomization strategy was used to

47 are not always feasible because of a lack of equipoise, the need to assess delayed endpoints, and con

48 There is enough equipoise to justify randomized, placebo-controlled tria

49 omodulatory therapy and that there is enough equipoise to justify randomized, placebo-controlled tria

50 tments encroached on their ability to convey equipoise to patients.

51 ments and their intentions for communicating equipoise to patients.

52 If so, there may be equipoise to test if VT less than or equal to 6 mL/kg pr

53 This evidence should shift clinicians' equipoise towards more restrictive transfusion practice.

54 nterviews revealed that clinicians' sense of equipoise varied: although all were uncertain about whic

55 However, equipoise was omitted or compromised in 48/105 (46%) of

56 First, equipoise was overridden by clinicians offering treatmen

57 Third, equipoise was undermined by clinicians disclosing their

58 urgeon experience are propelling CAS towards equipoise with and possible superiority to CEA.

59 artery stenting (CAS) has achieved clinical equipoise with carotid endarterectomy (CEA), as evidence